The investigational drug cobicistat (COBI), which boosts drug levels (a "pharmacoenhancer"), was given with Reyataz plus Truvada and compared to Norvir-boosted Reyataz plus Truvada, a preferred regimen under U.S. treatment guidelines. In Phase 3 study results after 48 weeks, cobicistat-boosted Reyataz was non-inferior to Norvir-boosted Reyataz, with high rates of virologic success (viral loads of less than 50 copies per mL) and similar safety and tolerability. Nearly 700 individuals participated in Study 114.
"Cobicistat appears to be an effective drug for boosting protease inhibitor levels, with greater potential for co-formulation," said presenter Joel Gallant, M.D., M.P.H. of Johns Hopkins University School of Medicine. He noted the various co-formulations of cobicistat with protease inhibitors that are in development. Moreover, he pointed out that, "[Norvir]-boosted Reyataz is known to be a lipid-friendly regimen and cobicistat is no different."
"This is all good news," said session co-facilitator Christine Katlama, M.D., of Hospitalier Pitie-Salpetriere in Paris, "because all the drugs work and when they don't work there is no resistance."
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|